VC  Hatteras Venture Partners

http://www.hatterasvp.com





     Office Locations:

280 S. Magnum St., Suite 350
Durham, NC 27701
Phone: 919-484-0730
Fax: 919-484-0364

 

Stages:

  • Early
  • Seed


 

Industries:

  • Life Sciences & Healthcare
  • Medical Device

  •  

    Description:

    Hatteras Venture Partners is a venture capital firm based in Research Triangle Park, N.C., with a focus on biopharmaceuticals, medical devices, diagnostics, and related opportunities in human medicine. Hatteras was founded in 2000 by John Crumpler and Clay Thorp with the launch of its first venture capital fund, Hatteras Venture Partners I, a pre-seed fund that has generated top decile returns focused predominantly on company formation in the life sciences. In 2004, the firm raised its second fund, Hatteras Venture Partners II, a later-stage fund invested through a partnership with HBM BioCapital. Currently, with four funds, the firm has more than $250 million under management. The first fund, HVP I, is a $3 million fund focused on pre-seed and company formation. The second fund, HVP II, is a $35 million investment in HBM BioCapital, through which Hatteras is an investment advisor. HVP III is an $83 million early-stage fund that invests in breakthrough discoveries that impact human medicine, and HVP IV, a fund launched with $74 million and reached its target size of $125 million on January 7, 2013, is also known as Hatteras Discovery, and is focused on seed-stage companies and projects in the field of human medicine and life sciences. The firm seeks to invest between $500,000 and $4 million initially and $5 to $10 million total in companies located in the U.S., with a preference for the Southeast and Mid-Atlantic.


     

    Funds:


      Fund Name


      Amount


      Date

    Get funds under management for this firm including Fund name, Dollar size of fund raise, and Vintage with a National Database subscription.



    Investment Firm Key

       VC = Venture Capital
       PE = Private Equity
       A = Angel
       I = Incubator
       MB = Merchant Bank
       VD = Venture Debt
       FI = Family Investment Office
       FOF = Fund of Funds
       ED = Economic Development Office   
       TT = Technology Transfer Office
       CVC = Corporate Venture Capital
       SEC = Secondary Purchaser
       HF = Hedge Fund/Mutual Fund
       
       
       
    COMPANY STAGEREVENUE
    Venture Capital
    Seed Stage
    (includes "pre-seed," or
    concept stage)
    No Revenue
    Early StageMinimal
    Revenue
    Growth Stage
    (also called Mid-stage)
    $2M-$7M
    Expansion Stage
    (also called Late-stage)
    $7M and greater
    Private Equity
    Lower Middle Market$10M-$249M
    Middle Market$250M-$499M
    Upper Middle Market$500M-$1B
    Large Cap>$1B
       
       
     

    Investment Team:


    Name   Title
    Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription.
    Clay Thorp General Partner
    Douglas Reed MD General Partner
    John C. Crumpler General Partner
    Kenneth Lee General Partner
    Robert Ingram General Partner

     

    Recent Funding Events (trailing 12 months):


      Date


      Name


      State


      Amount


      Stage


      06/13/2018


      StrideBio


      NC


      $15,700,000


      Series A


      10/31/2017


      Ribometrix


      NC


      $7,500,000


      Seed


      09/18/2017


      Rodin


      MA


      $27,000,000


      


      06/27/2017


      ORIG3N


      MA


      $20,000,000


      


     

    Portfolio companies include:


      Anthera Pharmaceuticals
        web link


      ArtusLabs
        web link


      Asthmatx
        web link


      Bivarus
        web link


      Boragen


      BRAHMS GmbH
        web link


      Broncus Technologies
        web link


      CancerGuide
        web link


      Clearside Biomedical
        web link


      Clinipace
        web link


      Clinipace Worldwide
        web link


      Clinverse
        web link


      Coferon
        web link


      Curoverse
        web link


      Delenex Therapeutics AG
        web link


      Devise Innovation Group
        web link


      Embrella Cardiovascular
        web link


      Entegrion
        web link


      ESBATech AG
        web link


      G1 Therapeutics
        web link


      HistoSonics
        web link


      Innocrin Pharmaceuticals
        web link


      KnowledgeTree
        web link


      Koltan Pharmaceuticals
        web link


      Lux Biosciences
        web link


      Lysosomal Therapeutics
        web link


      Medfusion
        web link


      Micardia Corporation
        web link


      Mpex Pharmaceuticals
        web link


      mtm Laboratories
        web link


      Nabriva Therapeutics
        web link


      Nereus Pharmaceuticals
        web link


      Newron
        web link


      Noverant
        web link


      ORIG3N
        web link


      Pathfinder
        web link


      Phase Bioscience
        web link


      PhaseBio Pharma
        web link


      Precimed Group
        web link


      Respirics
        web link


      Ribometrix
        web link


      Rodin
        web link


      Sideris Pharmaceuticals
        web link


      SpineAlign
        web link


      Spyryx Biosciences
        web link


      StrideBio
        web link


      SugarSync
        web link


      Synthematix
        web link


      TetraLogic
        web link


      Viamet Pharmaceuticals
        web link


      Zosano Pharma
        web link


     

    Recent News: